Recognizing a Visionary Leader in Advancing Healthcare Access for Minority and Vulnerable Populations Worldwide ATLANTA, GA - ...

Mpox, Oncology Therapies and AI Integration Positions GeoVax for Strong Momentum ATLANTA, GA - February 5, 2025 (NEWMEDIAWIRE ...

GeoVax Labs' Mpox vaccine still has a long way to go before gaining approval or generating any type of revenue. Its treatment is still in pre-clinical development. That phase of development alone ...

GeoVax Labs Inc (NASDAQ:GOVX) shares are trading lower Tuesday, pulling back from recent strength after the company announced an offering of 1.7 million shares at a price of $5 per share.

This versatility allows GeoVax to develop vaccines targeting multiple aspects of a single pathogen or several pathogens simultaneously. Originally developed as a safer smallpox vaccine ...

ATLANTA, GA - February 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a leader in vaccine and immunotherapy development, announced today its endorsement of President Donald J.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. GeoVax Labs ( NASDAQ:GOVX – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 12th.

Dr. Montgomery Rice will be formally recognized at the Atlanta Business Chronicle's second annual Health Care Champion Awards ceremony on March 20, 2025.

Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

ATLANTA, GA - February 5, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious ...